Lung Cancer
By Chase Doyle
Zepzelca (lurbinectedin), a recently approved drug for patients with metastatic (spreading) small-cell lung cancer, may be even safer than expected, according to data from 2 studies presented at the 2020 ASCO annual meeting. Read More ›
By Wayne Kuznar
Treatment with the targeted drug Tagrisso (osimertinib) as an adjuvant therapy (used in addition to primary therapy, such as surgery or chemotherapy) significantly reduces disease recurrence in patients with localized non–small-cell lung cancer (NSCLC) and an EGFR gene mutation (alteration). Read More ›
On May 29, 2020, the FDA approved the combination of Cyramza (ramucirumab; from Eli Lilly) in combination with Tarceva (erlotinib; from Astellas Pharma) for the first-line treatment of patients with metastatic non–small-cell lung cancer (NSCLC) and an EGFR exon 19 deletions or exon 21 (L858R) mutations. Read More ›
On May 26, 2020, the FDA approved a new indication for the combination of the PD-1 inhibitor Opdivo (nivolumab) and the CTLA-4 inhibitor Yervoy (ipilimumab; both from Bristol Myers Squibb) plus 2 cycles only of chemotherapy as the first-line treatment of patients with recurrent or metastatic non–small-cell lung cancer (NSCLC), including patients with squamous or nonsquamous NSCLC, regardless of PD-L1 expression, and no EGFR or ALK genomic aberrations. Read More ›
By Phoebe Starr
About 15% of lung cancers are small-cell lung cancer, and about one-third of those are extensive-stage small-cell lung cancer. In March 2020, the FDA approved the first immunotherapy, for use with chemotherapy, for first-line treatment of patients with extensive-stage small-cell lung cancer. Read More ›
In this last part of the series, we examine the full patient journey, from diagnosis through treatment, and provide a list of questions for patients to ask their doctors for more information.
Read More ›In June, the FDA approved Zepzelca as the newest treatment for patients with metastatic small-cell lung cancer, an uncommon type of lung cancer with few treatment options.
Read More ›
Non–small-cell lung cancer, or NSCLC, is the most common form of lung cancer, accounting for about 80% to 85% of all lung cancer cases in the United States.
Read More ›
Patients with advanced lung cancer should be tested for the 5 most common biomarkers so they may receive the best treatment options for their disease. Read More ›
In the second article of this 4-part series, the authors present an overview of the current treatment landscape for NSCLC, including a description of the most often used treatments and common questions that patients can ask their providers. Read More ›